title: Canagliflozin-Associated Acute Pancreatitis.
abstract: Canagliflozin is a new drug in class of sodium-glucose cotransporter 2 inhibitors used for treatment of type 2 diabetes mellitus. We describe a patient who developed moderately severe acute pancreatitis as an untoward consequence after being initiated on this drug. To the best of our knowledge, this is the first reported case of canagliflozin-associated acute pancreatitis in clinical literature.
authors.affiliation: Department of Hospital Medicine (UHS), United Hospital, Allina Health, St. Paul, MN.
authors.forename: Rajanshu
authors.initials: R
authors.lastname: Verma
mesh_terms: D000208:Acute Disease; D000068896:Canagliflozin / Q000009:adverse effects* / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D004636:Emergency Service, Hospital; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D010195:Pancreatitis / Q000139:chemically induced* / Q000175:diagnosis
chemical_list: D007004:Hypoglycemic Agents; D000068896:Canagliflozin